BPC-157 for Dogs: Evidence, Dosing and What Owners Should Know
Does BPC-157 work for dogs? Review beagle bioavailability, published canine doses, safety data, veterinary cases and where products are sold.
Peptide guides, price comparisons & research
Beginner-friendly guides grounded in peer-reviewed research. Compare prices, understand the science, and research smarter.
Retatrutide Interest Is Surging: The Timeline to Lilly's Planned 2027 FDA Submission
Is retatrutide FDA approved? Not yet. Follow Lilly's planned Q1 2027 submission timeline and the rise in search, testing and internal interest.
FDA Warned 13 Research-Peptide Sellers. Ten Are Still Selling Peptides.
PeptidePrices reviewed 13 FDA research-peptide warning letters. Ten warned businesses still sell peptides through public or account-gated storefronts.
What Is Eloralintide (LY3841136)? Trials, Safety, and Availability
Eloralintide is Lilly's selective amylin agonist in Phase 3. Review its Phase 2 weight-loss results, side effects, mechanism, and research-market status.
ARA-290 Peptide Dosage: Human Trial Doses, Nerve Repair, and Pricing
ARA-290 human trials tested 2 mg IV and 1, 4, or 8 mg SC. See why 4 mg stood out, the nerve-repair evidence, FDA status, and live pricing.
Retatrutide Expanded Access Is Open—but It Is Not a Public Launch
Lilly is reviewing limited retatrutide expanded-access requests. See who may qualify, how physician requests work, and what remains unknown.
DSIP Peptide: Why FDA Advisers Voted Against It
FDA advisers voted against adding DSIP peptide forms to the 503A Bulks List. See the vote, evidence gaps, and what the decision does not mean.
PCAC Recommends BPC-157, KPV, TB-500, and MOTS-c for 503A Compounding
FDA's PCAC voted 8-6-1 to recommend BPC-157, KPV, TB-500, and MOTS-c for the 503A Bulks List. Learn what the advisory votes do and do not change.
KLOW Peptide Blend: Ingredients, Evidence, and Risks
KLOW combines GHK-Cu, BPC-157, TB-500, and KPV. Review what each ingredient is, what human studies show, and what the full blend has not proved.
GLP-1 Microdosing: Evidence, Risks, and Real Cost
What does GLP-1 microdosing mean? Review the evidence, FDA-approved dose schedules, compounded-drug risks, advertised costs, and provider checks.
GHK-Cu for Skin, Hair, and Injections: Human Evidence
Does GHK-Cu help skin or hair? Compare human, animal, and laboratory evidence for topical copper peptides, hair claims, and injectable GHK-Cu.
Peptides for Women's Weight Loss: Evidence in 2026
Which weight-loss peptides have real evidence for women? Compare semaglutide, tirzepatide, compounded options, safety, and telehealth access.
Peptides for Women Over 40: Evidence and Red Flags
An evidence-first guide to peptides for women over 40: weight management, skin, recovery, sexual health, menopause limits, and safety red flags.
Introducing the PeptidePrices Chrome Extension: Automatic Partner Coupons at Checkout
Our free Chrome extension auto-applies PeptidePrices partner-vendor coupon codes at checkout, so you never miss a discount. No copy-pasting, no personal-data collection. Here is exactly what it does, how it works, and how to install it.
What Centenarians' Immune Systems Reveal About Longevity (and Where Research Peptides Actually Fit)
A 2026 Nature Reviews Immunology review maps how people who reach 100+ stay biologically young: lower NLRP3 inflammation, more autophagy, calmer cellular senescence, an intact gut barrier. The honest science, and where the longevity compounds people research fit, and don't.
BGE-102 and the Inflammaging Bet: An Oral NLRP3 Inhibitor Cut hsCRP ~85% in a Phase 1 Trial
BioAge's BGE-102, an oral NLRP3 inhibitor, drove ≥85% median hsCRP reductions in a Phase 1 obesity cohort. The honest read — the data, the CANTOS precedent, the crowded NLRP3 race, and what it means (and doesn't) for inflammaging.
The Gene Switch for Regeneration: How ALDH1A2 and Retinoic Acid Made Mice Regrow Lost Tissue
In a 2025 Science study, scientists restored regenerative wound healing in mice by switching ALDH1A2 back on — the enzyme that makes retinoic acid. Here's the honest science, plenty of sources, and what it does (and doesn't) mean for healing.
AI Is Designing Drugs Now: Insilico Medicine, AlphaFold, and the Honest State of AI in Peptide Design
A generative-AI-designed drug just published Phase 2a human data in Nature Medicine. Here's the honest breakdown of Insilico Medicine's rentosertib, what AlphaFold actually changed, how AI is being used to design new peptides — and why your semaglutide was not AI-designed.
How to verify a peptide COA
How to verify a peptide COA: named lab, batch match, and lab-portal lookup. Use the free /coa-check tool. Not medical advice.
The One-Shot Gene Therapy That Wants to Replace Weekly Semaglutide: Fractyl's Rejuva, Explained
Fractyl's Rejuva (RJVA-001) is an experimental AAV gene therapy designed to make your own pancreas produce GLP-1 — a potential one-time alternative to weekly semaglutide. The mechanism, the preclinical data, the May 2026 first-in-human authorization, and the honest caveats about a treatment you can't undo.
Peptide Fulfillment for Research Brands: Our RapidFulfillment Partnership
RapidFulfillment is PeptidePrices' fulfillment and cold-chain logistics partner for research peptide brands — RUO peptide fulfillment, white-label dropshipping, and cold-chain logistics. Mention PeptidePrices for $300 off your fulfillment deposit.
RLS-1496, Explained: A First-in-Class GPX4 Cream That Targets 'Senescent' Skin Cells
RLS-1496 is Rubedo Life Sciences' first-in-class topical GPX4 modulator — a cream designed to clear senescent 'zombie' skin cells via ferroptosis. The Phase 1 and Phase 1b/2a data across psoriasis, atopic dermatitis, photoaging and actinic keratosis (a company-reported 46% lesion drop in 4 weeks), the 'senoadaptive' thesis, and the honest caveats.
The One-Time Shot That Edits Your DNA to Lower Cholesterol: VERVE-102, Explained
VERVE-102 is a single-infusion gene-editing therapy that permanently switches off the PCSK9 gene to lower LDL cholesterol. The Heart-2 trial data, the VERVE-101 safety scare, the $1.3B Lilly buyout, and the honest caveats about a treatment you can't undo.
What the GLP-1 Pipeline Showed at ADA 2026: Retatrutide, CagriSema, Orforglipron
The ADA's 86th Scientific Sessions (June 5–8, 2026) dumped the year's biggest GLP-1 data: retatrutide's ~28% weight loss, CagriSema's first diabetes trials, and orforglipron's oral readout. A plain-English roundup — including the caveats.
BPC-157's Human-Evidence Problem: What the Trials Actually Show
BPC-157 has a huge, impressive animal-research literature and almost no human-trial data. Both are true. Here's exactly what's been published in people — the PL-14736 program, the registered-but-unpublished trial — and why the gap matters.
SS-31 (Elamipretide): The Mitochondrial Peptide That Just Became an FDA Drug
On Sept 19, 2025, SS-31 became FORZINITY — the first FDA-approved drug to directly target the mitochondria. But the approval is for an ultra-rare disease, and the broad anti-aging story is messier than the headline. What the cardiolipin-binding peptide actually does, and doesn't.
GLP-1s Are Becoming "Everything" Drugs: The New Indications Beyond Weight Loss
GLP-1s are no longer just diabetes and weight-loss drugs. A clear-eyed map of what's actually FDA-approved (heart, sleep apnea, MASH), what has strong trial data (kidney), and what has failed or is still hype (Alzheimer's, addiction).
The Cholesterol Pill That's Secretly a Peptide: Enlicitide, Explained
Enlicitide (Merck's former MK-0616) is a once-daily cholesterol pill that's really an oral macrocyclic peptide — engineered to survive the gut. The Phase 3 CORALreef data, the empty-stomach catch, and what it signals for oral peptide drugs.
The FDA's July 2026 Peptide Hearing: What's Actually on the Table
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews 7 peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) for the 503A compounding list, with 5 more by early 2027. Here's what the hearing means, and what it doesn't.
The First GLP-1 Pill Is Here: What Orforglipron (Foundayo) Actually Is
Orforglipron (Foundayo) is the first oral GLP-1 approved for weight loss, and, surprisingly, it's a non-peptide small molecule, not a peptide. Here's how it works, the ATTAIN trial numbers, and how it stacks up against injectable semaglutide and tirzepatide.
What the Peptide Skeptics Agree On: Topol, Attia & Saladino
Three credible voices, cardiologist Eric Topol, Peter Attia, and Paul Saladino, have pushed back on the peptide boom. Here's where they actually converge: the human-trial evidence gap, the GLP-1 exception, and the gray-market quality problem.
Dr. Paul Saladino's Peptide Breakdown: "No Biological Free Lunch"
Dr. Paul Saladino's YouTube breakdown of peptides, GLP-1s, BPC-157/TB-500, GH secretagogues, melanotan, sorted into what's effective, what's risky, and why he argues there's no biological free lunch. We separate his verifiable points from his strong opinions.
Huberman's Peptide Episode with Dr. Abud Bakri: The Full Breakdown
A clear, fact-checked breakdown of the Huberman Lab peptides episode with Dr. Abud Bakri — BPC-157, GLP-1s, the Russian bioregulators, the thymus, GH secretagogues, and the gray-market reality. We separate the established science from the anecdotes.
Drug or Biologic? The Lilly–FDA Fight Over Retatrutide, Explained
Eli Lilly is fighting the FDA over whether retatrutide is a small-molecule drug or a biologic, a distinction that turns on amino-acid counting and could reshape competition, compounding, and the obesity-drug market. Here's what's actually at stake.
How to Vet a Peptide Vendor: A Buyer's Checklist
Six concrete criteria for checking whether a peptide vendor is trustworthy — named labs, batch COAs, endotoxin, address, track record, reviews.
Best Peptides for Joint Pain, Tendons, and Ligaments (2026)
Looking at peptides for joint pain or tendon recovery? We rank the 7 most-researched options by evidence quality, side-effect profile, and current 2026 vendor pricing.